Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, an enzyme that determines the reaction rate and converts 3-hydroxy-3-methylglutaryl coenzyme A into mevalonate, the precursor of cholesterol. The main place of action of rosuvastatin is the liver, the target organ for reducing cholesterol levels.
Rosuvastatin increases the number of low-density lipoprotein (LDL) receptors on the surface of the liver cells, enhancing the uptake and catabolism of LDL, and inhibits the hepatic synthesis of very low-density lipoproteins (VLDL), thereby reducing the total number of VLDL and LDL particles.
Trade name: Rosuvastatin IC
Pharmaceutical form: tablets – 5 mg, 10 mg, 20 mg and 40 mg
Pharmacotherapeutic group: Lipid-lowering drugs. Inhibitors of HMG-CoA reductase. Rosuvastatin.
Code ATX C10A A07.
Registration number: №UA/15855/01/01, №UA/15855/01/02, №UA/15855/01/03, №UA/15855/01/04
Date of registration / valid until: 09.03.2017 / 09.03.2022
Packing: tablets № 30 (10 × 3) in a blister pack
Shelf life: 3 years
Legal category: prescription only medicine
Search